nektar therapeutics is a leading biopharmaceutical company developing a robust pipeline of novel therapeutics based on its advanced polymer conjugate chemistry technology platform. nektar also partners with the top biopharmaceutical companies to bring new products to market. to date, nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies.
Company profile
Ticker
NKTR
Exchange
Website
CEO
Howard Robin
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
INHALE THERAPEUTIC SYSTEMS INC, INHALE THERAPEUTIC SYSTEMS
SEC CIK
Corporate docs
Subsidiaries
Inheris Biopharma, Inc. ...
IRS number
943134940
NKTR stock data
Latest filings (excl ownership)
S-3
Shelf registration
28 May 24
8-K
Nektar Therapeutics Reports First Quarter 2024 Financial Results
9 May 24
ARS
2023 FY
Annual report to shareholders
26 Apr 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
8-K
Other Events
17 Apr 24
D
$30.00 mm in equity / options, sold $30.00 mm, 1 investor
19 Mar 24
10-K
2023 FY
Annual report
5 Mar 24
8-K
Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results
4 Mar 24
8-K
Entry into a Material Definitive Agreement
4 Mar 24
Transcripts
NKTR
Earnings call transcript
2024 Q1
9 May 24
NKTR
Earnings call transcript
2023 Q4
4 Mar 24
NKTR
Earnings call transcript
2023 Q3
7 Nov 23
NKTR
Earnings call transcript
2023 Q2
8 Aug 23
NKTR
Earnings call transcript
2023 Q1
9 May 23
NKTR
Earnings call transcript
2022 Q3
4 Nov 22
NKTR
Earnings call transcript
2022 Q2
4 Aug 22
NKTR
Earnings call transcript
2021 Q4
1 Mar 22
NKTR
Earnings call transcript
2021 Q3
5 Nov 21
NKTR
Earnings call transcript
2021 Q2
6 Aug 21
Latest ownership filings
4
HOWARD W ROBIN
20 May 24
4
Jonathan Zalevsky
20 May 24
4
Mark Andrew Wilson
20 May 24
144
Notice of proposed sale of securities
17 May 24
144
Notice of proposed sale of securities
17 May 24
144
Notice of proposed sale of securities
17 May 24
4
DAVID KROIN
13 May 24
SC 13G
TCG Crossover GP II, LLC
15 Mar 24
3
DAVID KROIN
14 Mar 24
4
Jonathan Zalevsky
22 Feb 24
Financial summary
Quarter (USD) | Dec 23 | Sep 23 | Jun 23 | Mar 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 35.28 mm | 35.28 mm | 35.28 mm | 35.28 mm | 35.28 mm | 35.28 mm |
Cash burn (monthly) | 9.88 mm | 4.41 mm | 14.04 mm | 23.02 mm | 15.68 mm | 16.05 mm |
Cash used (since last report) | 50.44 mm | 22.52 mm | 71.65 mm | 117.52 mm | 80.05 mm | 81.93 mm |
Cash remaining | -15.16 mm | 12.75 mm | -36.37 mm | -82.24 mm | -44.78 mm | -46.66 mm |
Runway (months of cash) | -1.5 | 2.9 | -2.6 | -3.6 | -2.9 | -2.9 |
Institutional ownership, Q1 2024
13.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 39 |
Opened positions | 26 |
Closed positions | 3 |
Increased positions | 0 |
Reduced positions | 3 |
13F shares | Current |
---|---|
Total value | 2.70 bn |
Total shares | 25.16 mm |
Total puts | 0.00 |
Total calls | 131.40 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
TCG Crossover GP II | 20.05 mm | $18.24 mm |
Gsa Capital Partners | 1.99 mm | $1.86 mm |
Assenagon Asset Management | 1.69 mm | $1.58 bn |
Susquehanna International | 381.00 k | $355.93 mm |
Marquette Asset Management | 232.29 k | $217.01 mm |
Cambridge Investment Research Advisors | 126.01 k | $118.00 k |
Moloney Securities Asset Management | 105.11 k | $98.19 mm |
Russell Investments | 82.43 k | $77.01 mm |
State Board Of Administration Of Florida Retirement System | 67.44 k | $47.40 mm |
Diversified Trust | 60.21 k | $56.25 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
17 May 24 | Zalevsky Jonathan | Common Stock | Sell | Dispose S | No | No | 1.75 | 7,355 | 12.87 k | 257,670 |
17 May 24 | Mark Andrew Wilson | Common Stock | Sell | Dispose S | No | No | 1.75 | 6,260 | 10.96 k | 230,414 |
17 May 24 | Robin Howard W | Common Stock | Sell | Dispose S | No | No | 1.75 | 16,650 | 29.14 k | 863,239 |
10 May 24 | Deep Track Capital | Common Stock | Sell | Dispose S | Yes | No | 1.7791 | 56,000 | 99.63 k | 18,344,000 |
News
Nektar Therapeutics Q1 2024 GAAP EPS $(0.19) Beats $(0.20) Estimate, Sales $21.639M Beat $15.342M Estimate
9 May 24
12 Health Care Stocks Moving In Tuesday's After-Market Session
7 May 24
Nektar Therapeutics Receives Letter That It Has Regained Compliance With Minimum Bid Price Requirement For Continued Listing On Nasdaq Capital Market - Filing
17 Apr 24
12 Health Care Stocks Moving In Thursday's Intraday Session
11 Apr 24
Jefferies Maintains Hold on Nektar Therapeutics, Raises Price Target to $1
6 Mar 24
Press releases
Nektar Management to Present at Upcoming Investor Conferences
30 May 24
Nektar Therapeutics Reports First Quarter 2024 Financial Results
9 May 24
Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets
2 May 24
Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
22 Mar 24